- Home
- AVIR vs SVIA Comparison
AVIR vs SVIA Comparison
Compare AVIR & SVIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$4.17
Company Overview
Basic Information| Metric | AVIR | SVIA |
|---|---|---|
| Founded | 2012 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.1M | 333.9M |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | AVIR | SVIA |
|---|---|---|
| Price | $4.17 | $3.47 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 277.8K | ★ 1.2M |
| Earning Date | 11-11-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.87 | $3.40 |
| 52 Week High | $6.45 | $4.74 |
Technical Indicators
Market Signals| Indicator | AVIR | SVIA |
|---|---|---|
| Relative Strength Index (RSI) | 30.76 | 40.91 |
| Support Level | $4.06 | $3.40 |
| Resistance Level | $4.46 | $3.95 |
| Average True Range (ATR) | 0.25 | 0.27 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 17.69 | 13.11 |
Price Performance
Historical Comparison AVIR
SVIA
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.